CELESTIAL-TNCLL
CELESTIAL-TNCLL tests the next-generation all-oral doublet against the current fixed-duration standard, with results expected from late 2026.
Phase 3 following BGB-11417-101, where sonrotoclax + zanubrutinib produced uMRD in almost all treatment-naive patients by week 96 including high-risk genetics. Estimated primary completion November 2026. A companion trial tests the doublet vs zanubrutinib alone.
Pages like this
not linked directly; found by shared links- TrialCAPTIVATE
Shares MRD-guided treatment duration in CLL, BTK inhibitor + venetoclax, fixed duration, BTK (Bruton tyrosine kinase), BCL-2.
- TrialGLOW
Shares BTK inhibitor + venetoclax, fixed duration, Obinutuzumab, BTK (Bruton tyrosine kinase), BCL-2.
- TrialAMPLIFY
Shares BTK inhibitor + venetoclax, fixed duration, Obinutuzumab, BTK (Bruton tyrosine kinase), BCL-2.
- TrialSEQUOIA
Shares BTK inhibitor + venetoclax, fixed duration, Zanubrutinib, BTK (Bruton tyrosine kinase), Venetoclax.
- IdeaBTK degraders to pre-empt resistance in frontline CLL
Shares Sonrotoclax, BTK (Bruton tyrosine kinase), BCL-2, Venetoclax.
- Key paperAMPLIFY: fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, versus chemo-immunotherapy in fit CLL patients
Shares BTK inhibitor + venetoclax, fixed duration, Obinutuzumab, BTK (Bruton tyrosine kinase), BCL-2.
- PairingVenetoclax + obinutuzumab (12 months)
Shares Obinutuzumab, BCL-2, Venetoclax, Chronic lymphocytic leukaemia.
- TrialALPINE
Shares Zanubrutinib, BTK (Bruton tyrosine kinase), Chronic lymphocytic leukaemia.